SciSparc (Nasdaq: SPRC) launches Phase IIb SCI-110 Tourette study

Rhea-AI Filing Summary

SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reports the launch and progression of a Phase IIb clinical trial of SCI-110 at the Yale Child Study Center for adults with Tourette Syndrome. SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dosage form aimed at reducing tics while limiting side effects.

The multicenter study also runs at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel and builds on Phase IIa results that showed an average 21% tic reduction across participants on the Yale Global Tic Severity Scale. The Phase IIb trial is randomized, double-blind, placebo-controlled and cross-over, enrolling patients aged 18–65 and assessing tic severity changes at weeks 12 and 26.

Filing Explained

The Form 6-K furnishes SciSparc’s press release and incorporates specified portions into its listed Form F-3 and Form S-8 registration statements, updating those registration documents without reporting an issuance or sale of shares in this filing.

Key Figures

Average tic reduction in Phase IIa: 21% Patient age range in Phase IIb trial: 18-65 years Primary endpoint assessment times: Weeks 12 and 26 +1 more

4 metrics

Average tic reduction in Phase IIa 21% Average reduction in tics across participants on the Yale Global Tic Severity Scale in the Phase IIa study

Patient age range in Phase IIb trial 18-65 years Age range of adults enrolled in the Phase IIb SCI-110 trial for Tourette Syndrome

Primary endpoint assessment times Weeks 12 and 26 Tic severity on the Yale Global Tic Severity Scale assessed at weeks 12 and 26 versus baseline

Investor contact telephone +972-3-6167055 Telephone number provided for investor contact

Key Terms

Phase IIb, randomized, double-blind, placebo-controlled, cross-over trial, Yale Global Tic Severity Scale, Tourette Syndrome, +1 more

5 terms

Phase IIb medical

"NeuroThera’s Phase IIb clinical trial site at the Yale Child Study Center"

Phase IIb is a mid-stage clinical trial that tests whether an experimental treatment works and what dose is best by studying it in a larger group of patients than early tests. For investors, Phase IIb results are important because they substantially reduce uncertainty about a drug’s effectiveness and safety, and positive or negative outcomes often drive company valuation, partnership interest, and the likelihood of advancing to the large, costly Phase III trials.

randomized, double-blind, placebo-controlled, cross-over trial medical

"the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial"

Yale Global Tic Severity Scale medical

"measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score"

A clinician-rated questionnaire that measures the severity and impact of motor and vocal tics, including number, frequency, intensity, complexity and overall impairment. Think of it like a standardized report card for tics used in clinical care and drug trials; it matters to investors because scores are commonly used as an objective endpoint in research and regulatory filings, which can influence trial outcomes, approval prospects and commercial value of treatments.

Tourette Syndrome medical

"drug candidate for the treatment of Tourette Syndrome in adults"

Tourette syndrome is a neurological condition that causes repeated, involuntary movements or sounds known as tics, which typically begin in childhood and vary widely in severity. Investors pay attention because it creates a defined need for medical treatments, therapies, and support services—similar to how recurring software bugs create demand for updates—affecting market size, regulatory scrutiny, clinical trial opportunities and potential workforce or cost implications for healthcare and education sectors.

endocannabinoid-like medical

"dronabinol with the endocannabinoid-like palmitoylethanolamide in a single dosage form"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/05/2026 - 09:00 AM Accepted by SEC EDGAR 08/05/2026 - 09:00 AM Learn about SEC filing dates

FAQ

What did SciSparc Ltd. (SPRC) announce about SCI-110 and Tourette Syndrome?

SciSparc, via its majority-owned subsidiary NeuroThera Labs, announced a Phase IIb clinical trial of SCI-110 at the Yale Child Study Center to evaluate this cannabinoid-based drug candidate as a treatment for Tourette Syndrome in adults.

What were the key Phase IIa results for SciSparc (SPRC) drug candidate SCI-110?

The Phase IIa study of SCI-110 showed an average 21% tic reduction across all participants, measured by the Yale Global Tic Severity Scale Total Tic Score, supporting advancement into the current Phase IIb trial in adults with Tourette Syndrome.

How is the Phase IIb SCI-110 trial for SciSparc (SPRC) designed?

The Phase IIb SCI-110 study is a randomized, double-blind, placebo-controlled, cross-over trial. Adults aged 18-65 receive daily oral SCI-110 or placebo, with primary efficacy based on tic severity changes at weeks 12 and 26 versus baseline.

Where are SciSparc (SPRC) and NeuroThera Labs conducting the Phase IIb SCI-110 trial?

The Phase IIb SCI-110 trial is being conducted at the Yale Child Study Center in the U.S., Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel as part of a global development program for Tourette Syndrome.

What conditions is SciSparc Ltd. (SPRC) targeting with its cannabinoid-based pipeline?

SciSparc, through NeuroThera, is developing cannabinoid-based programs including SCI-110 for Tourette Syndrome and for Alzheimer’s disease and agitation, and SCI-210 for autism spectrum disorder and status epilepticus, plus a hemp seed oil product business on Amazon.com.

What is the primary efficacy endpoint in SciSparc (SPRC) Phase IIb SCI-110 trial?

The primary endpoint is the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline, with safety evaluated through monitoring of adverse events in treated adults with Tourette Syndrome.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2026

Commission File Number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒     Form 40-F ☐

CONTENTS

On August 5, 2026, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Report”) and is incorporated by reference herein.

The first three and the fifth paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408, 333-293167 and 333-293533) and on Form S-8 (File Nos. 333-278437, 333-225773, 333-286791 and 333-292952) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release issued by SciSparc Ltd. titled “SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SCISPARC LTD.
	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer

Date: August 5, 2026

3

Exhibit 99.1

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

TEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or ”SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced the initiation of NeuroThera’s Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera’s proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome (“TS”) in adults.

The trial is now progressing at the Yale Child Study Center, one of the study’s key clinical sites. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in a single, innovative dosage form designed to reduce tics and associated comorbid symptoms in adults with TS while aiming to minimize side effects.

In addition to the Yale site, the Phase IIb trial is also underway at Hannover Medical School in Hanover, Germany, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.

Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera, commented: “Launching a U.S. site at the Yale Child Study Center represents a significant milestone in our global development program for SCI-110. TS remains a major unmet medical need with limited therapeutic options, particularly in adults who continue to experience persistent, severe, and often debilitating symptoms. We believe SCI-110 has the potential to introduce a novel, more effective and safer treatment approach. We are deeply committed to advancing this promising therapy and generating meaningful clinical data to support NeuroThera’s future regulatory approval.”

Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits, safety efficacy, advantages and capabilities of SCI-110 and the Company’s belief that SCI-110 has the potential to introduce a novel, more effective and safer treatment approach. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LA 9.3 KB